

# Giovanna Borriello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/873358/publications.pdf>

Version: 2024-02-01

44  
papers

1,845  
citations

361413

20  
h-index

265206

42  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2481  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disability assessment using Google Maps. <i>Neurological Sciences</i> , 2022, 43, 1007-1014.	1.9	10
2	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	3.0	37
3	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	3.3	8
4	Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, 3396-3402.	3.3	36
5	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.3	370
6	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. <i>Journal of Neurology</i> , 2021, 268, 2922-2932.	3.6	18
7	Long-term fingolimod treatment in two pediatric patients with multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 29-36.	1.9	1
8	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021, 10, 1234.	2.4	10
9	Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7338.	2.6	4
10	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
11	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020, 267, 694-702.	3.6	6
12	Cesarean section in women with MS: A choice or a need?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101867.	2.0	3
13	COVID-19 pandemic and mental distress in multiple sclerosis: implications for clinical management. <i>European Journal of Neurology</i> , 2020, 28, 3375-3383.	3.3	47
14	Case Report: Concurrent Resistance and Aerobic Training Regulate Adiponectin Expression and Disease Severity in Multiple Sclerosis: A Case Study. <i>Frontiers in Neuroscience</i> , 2020, 14, 567302.	2.8	4
15	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020, 41, 3185-3193.	1.9	15
16	COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102165.	2.0	35
17	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	3.6	19
18	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. <i>Frontiers in Neurology</i> , 2020, 11, 105.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. <i>Neurology</i> , 2019, 93, e733-e746.	1.1	21
20	The Effects of Concurrent Resistance and Aerobic Exercise Training on Functional Status in Patients with Multiple Sclerosis. <i>Current Sports Medicine Reports</i> , 2019, 18, 452-457.	1.2	30
21	Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 239-246.	2.0	9
22	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. <i>Journal of Neurology</i> , 2019, 266, 411-416.	3.6	20
23	Why physical activity improves quality of life in multiple sclerosis patients: correlation between fatigue and functional parameters. <i>Medicina Dello Sport</i> , 2019, 72, .	0.1	1
24	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879640.	3.5	26
25	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. <i>CNS Drugs</i> , 2018, 32, 963-970.	5.9	35
26	Effects of an unconventional re-walking training on physical, psychological, and cognitive impairment in multiple sclerosis patients. <i>Medicina Dello Sport</i> , 2018, 71, .	0.1	1
27	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 154-171.	2.0	4
28	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	5.0	13
29	A Low-Cost Cognitive Rehabilitation With a Commercial Video Game Improves Sustained Attention and Executive Functions in Multiple Sclerosis. <i>Neurorehabilitation and Neural Repair</i> , 2015, 29, 453-461.	2.9	60
30	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1106-1112.	3.0	56
31	MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1337-1339.	3.0	15
32	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 64-71.	3.0	85
33	Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2012, 323, 104-112.	0.6	47
34	Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. <i>European Journal of Neurology</i> , 2012, 19, 783-787.	3.3	43
35	Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?. <i>BMC Neurology</i> , 2011, 11, 26.	1.8	19
36	Observations during an elective interruption of natalizumab treatment: a post-marketing study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 372-375.	3.0	33

#	ARTICLE	IF	CITATIONS
37	Treating multiple sclerosis with fingolimod or intramuscular interferon. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1957-1960.	1.8	4
38	Natalizumab treatment in pediatric multiple sclerosis: A case report. <i>European Journal of Paediatric Neurology</i> , 2009, 13, 67-71.	1.6	59
39	One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. <i>European Journal of Neurology</i> , 2009, 16, 1202-1209.	3.3	122
40	Emerging oral drugs for multiple sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 465-477.	2.4	17
41	Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. <i>Clinical Rehabilitation</i> , 2007, 21, 331-337.	2.2	96
42	Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. <i>European Journal of Neurology</i> , 2007, 14, 1281-1287.	3.3	20
43	Real time PCR for detection of <i>Chlamydomphila pneumoniae</i> in peripheral blood mononuclear cells of patients with multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 1293-1295.	3.6	6
44	fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. <i>NeuroImage</i> , 2004, 21, 858-867.	4.2	285